Response to Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255
- From Temple University Hospital, Philadelphia, Pennsylvania
- Address correspondence to Guenther Boden, Temple University Health Science Center, General Clinical Research Center, 3401 North Broad St., 4W, Philadelphia, Pennsylvania 19140-6148. E-mail: bodengh{at}tuhs.temple.edu
We appreciated the comments by Dr. Stroup (1) who wonders whether the baseline (pretreatment) risk for edema might have been higher in the rosiglitazone-treated group as compared with the rosiglitazone plus fenofibrate–treated group. Specifically, he asks how many patients in each group had a history of congestive heart failure or …
